BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38326851)

  • 1. Neuroendocrine and squamous cell phenotypes of NUT carcinoma are potential diagnostic pitfalls that discriminating it from mimickers, such as small cell and squamous cell carcinoma.
    Ninomiya H; Sato Y; Inamura K; Dobashi A; Takeuchi K; Mitani H; Mun M; Nishio M; Ishikawa Y
    Diagn Pathol; 2024 Feb; 19(1):27. PubMed ID: 38326851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulinoma-associated Protein 1 (INSM1) Is a Better Marker for the Diagnosis and Prognosis Estimation of Small Cell Lung Carcinoma Than Neuroendocrine Phenotype Markers Such as Chromogranin A, Synaptophysin, and CD56.
    Sakakibara R; Kobayashi M; Takahashi N; Inamura K; Ninomiya H; Wakejima R; Kitazono S; Yanagitani N; Horiike A; Ichinose J; Matsuura Y; Nakao M; Mun M; Nishio M; Okumura S; Motoi N; Ito T; Miyazaki Y; Inase N; Ishikawa Y
    Am J Surg Pathol; 2020 Jun; 44(6):757-764. PubMed ID: 32118626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulinoma-associated protein 1 (INSM1) is a sensitive and highly specific marker of neuroendocrine differentiation in primary lung neoplasms: an immunohistochemical study of 345 cases, including 292 whole-tissue sections.
    Mukhopadhyay S; Dermawan JK; Lanigan CP; Farver CF
    Mod Pathol; 2019 Jan; 32(1):100-109. PubMed ID: 30154579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of novel neuroendocrine marker insulinoma-associated protein 1 (INSM1) in genitourinary high-grade neuroendocrine carcinomas: An immunohistochemical study with specificity analysis and comparison to chromogranin, synaptophysin, and CD56.
    Chen JF; Yang C; Sun Y; Cao D
    Pathol Res Pract; 2020 Jun; 216(6):152993. PubMed ID: 32381384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. INSM1 Demonstrates Superior Performance to the Individual and Combined Use of Synaptophysin, Chromogranin and CD56 for Diagnosing Neuroendocrine Tumors of the Thoracic Cavity.
    Rooper LM; Sharma R; Li QK; Illei PB; Westra WH
    Am J Surg Pathol; 2017 Nov; 41(11):1561-1569. PubMed ID: 28719469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. INSM1 Is Less Sensitive But More Specific Than Synaptophysin in Gynecologic High-grade Neuroendocrine Carcinomas: An Immunohistochemical Study of 75 Cases With Specificity Test and Literature Review.
    Zou Q; Zhang L; Cheng Z; Guo X; Cao D
    Am J Surg Pathol; 2021 Feb; 45(2):147-159. PubMed ID: 33264139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. INSM1 expression in a subset of thoracic malignancies and small round cell tumors: rare potential pitfalls for small cell carcinoma.
    Tsai HK; Hornick JL; Vivero M
    Mod Pathol; 2020 Aug; 33(8):1571-1580. PubMed ID: 32203089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic Value of Insulinoma-Associated Protein 1 (INSM1) and Comparison With Established Neuroendocrine Markers in Pulmonary Cancers.
    Staaf J; Tran L; Söderlund L; Nodin B; Jirström K; Vidarsdottir H; Planck M; Mattsson JSM; Botling J; Micke P; Brunnström H
    Arch Pathol Lab Med; 2020 Sep; 144(9):1075-1085. PubMed ID: 31913660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of INSM1 in Diagnosis and Grading of Laryngeal Neuroendocrine Carcinoma.
    Yuan C; Jiao F; Zhai C; Zhang J; Wang S; Zhu L
    Laryngoscope; 2021 Oct; 131(10):E2662-E2668. PubMed ID: 33847383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of Synaptophysin, Chromogranin and CD56 in adenocarcinoma and squamous cell carcinoma of the lung lacking morphological features of neuroendocrine differentiation: a retrospective large-scale study on 1170 tissue samples.
    Kriegsmann K; Zgorzelski C; Muley T; Christopoulos P; Thomas M; Winter H; Eichhorn M; Eichhorn F; von Winterfeld M; Herpel E; Goeppert B; Stenzinger A; Herth FJF; Warth A; Kriegsmann M
    BMC Cancer; 2021 May; 21(1):486. PubMed ID: 33933015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SOX11 is a sensitive and specific marker for pulmonary high-grade neuroendocrine tumors.
    Yu L; Dong Y; Xue J; Xu S; Wang G; Kuang D; Duan Y
    Diagn Pathol; 2022 Jan; 17(1):2. PubMed ID: 34996493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. INSM1 Is More Sensitive and Interpretable than Conventional Immunohistochemical Stains Used to Diagnose Merkel Cell Carcinoma.
    Lilo MT; Chen Y; LeBlanc RE
    Am J Surg Pathol; 2018 Nov; 42(11):1541-1548. PubMed ID: 30080705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Squamous and Neuroendocrine Specific Immunohistochemical Markers in Head and Neck Squamous Cell Carcinoma: A Tissue Microarray Study.
    Lewis JS; Chernock RD; Bishop JA
    Head Neck Pathol; 2018 Mar; 12(1):62-70. PubMed ID: 28528398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nuclear Insulinoma-Associated Protein 1 Expression as a Marker of Neuroendocrine Differentiation in Neoplasms of the Breast.
    Seijnhaeve E; Galant C; Van Bockstal MR
    Int J Surg Pathol; 2021 Aug; 29(5):496-502. PubMed ID: 33426999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploration of INSM1 and hASH1 as additional markers in lung cytology samples of high-grade neuroendocrine carcinoma with indeterminate neuroendocrine differentiation.
    Rothrock AT; Stewart J; Li F; Racila E; Amin K
    Diagn Cytopathol; 2022 May; 50(5):230-234. PubMed ID: 35147301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of novel neuroendocrine markers in breast carcinomas: a study of INSM1, ASCL1, and POU2F3.
    Zhong E; Pareja F; Hanna MG; Jungbluth AA; Rekhtman N; Brogi E
    Hum Pathol; 2022 Sep; 127():102-111. PubMed ID: 35690220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic Utility of INSM1 in Medullary Thyroid Carcinoma.
    Seok JY; Kang M; De Peralta-Venturina M; Fan X
    Int J Surg Pathol; 2021 Sep; 29(6):615-626. PubMed ID: 33650906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of secretagogin as a marker for the diagnosis of lung neuroendocrine carcinoma.
    Baykara Y; Xiao Y; Yang D; Yakirevich E; Maleki S; Garcia-Moliner M; Wang LJ; Huang CK; Lu S
    Virchows Arch; 2022 Jul; 481(1):31-39. PubMed ID: 35357570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of neuroendocrine markers in non-neuroendocrine endometrial carcinomas.
    Moritz AW; Schlumbrecht MP; Nadji M; Pinto A
    Pathology; 2019 Jun; 51(4):369-374. PubMed ID: 31040050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. INSM1 is a novel prognostic neuroendocrine marker for luminal B breast cancer.
    Razvi H; Tsang JY; Poon IK; Chan SK; Cheung SY; Shea KH; Tse GM
    Pathology; 2021 Feb; 53(2):170-178. PubMed ID: 32951906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.